Table 1.
HPV DNA positivity | BCC (n=98) | SCC (n=98) | OR (95% CI)1 |
---|---|---|---|
Overall | |||
No β-types positive | 22 (22.4) | 16 (16.3) | Referent |
Any β-HPV | 76 (77.6) | 82 (83.7) | 1.5 (0.7–3.5) |
Previously reported types | |||
No or other β-types | 58 (59.2) | 37 (37.8) | Referent |
HPV 5, 8, 15, 20, 24, 36, and/or 38 | 40 (40.8) | 61 (62.2) | 2.6 (1.4–5.1) |
Multiple infection | |||
No or 1 β-type | 49 (50.0) | 32 (32.7) | Referent |
More than 1 β-type | 49 (50.0) | 66 (67.3) | 2.0 (1.0–3.9) |
Phylogenic species | |||
No β1 HPV | 52 (53.1) | 35 (35.7) | Referent |
Any β1 HPV | 46 (46.9) | 63 (64.3) | 2.0 (1.1–3.6) |
HPV 5 | 5 (5.1) | 6 (6.1) | |
HPV 8 | 4 (4.1) | 6 (6.1) | |
HPV 12 | 1 (1.0) | 5 (5.1) | |
HPV 14 | 1 (1.0) | 4 (4.1) | |
HPV 19 | 0 (0.0) | 3 (3.1) | |
HPV 20 | 7 (7.1) | 9 (9.2) | |
HPV 21 | 3 (3.1) | 6 (6.1) | |
HPV 24 | 9 (9.2) | 15 (15.3) | |
HPV 25 | 0 (0.0) | 0 (0.0) | |
HPV 36 | 18 (18.4) | 20 (20.4) | |
HPV 47 | 5 (5.1) | 5 (5.1) | |
HPV 93 | 18 (18.4) | 15 (15.3) | |
No β2 HPV | 42 (42.9) | 32 (32.7) | Referent |
Any β2 HPV | 56 (57.1) | 66 (67.3) | 1.4 (0.7–2.5) |
HPV 9 | 18 (18.4) | 23 (23.5) | |
HPV 15 | 14 (14.3) | 25 (25.5) | |
HPV 17 | 16 (16.3) | 24 (24.5) | |
HPV 22 | 2 (2.0) | 5 (5.1) | |
HPV 23 | 19 (19.4) | 20 (20.4) | |
HPV 37 | 12 (12.2) | 12 (12.2) | |
HPV 38 | 10 (10.2) | 15 (15.3) | |
HPV 80 | 9 (9.2) | 15 (15.3) | |
No β3, β4, and/or β5 HPV | 69 (70.4) | 66 (67.3) | Referent |
Any β3, β4, and/or β5 HPV | 29 (29.6) | 32 (32.7) | 1.0 (0.5–2.0) |
HPV 49 | 0 (0.0) | 6 (6.1) | |
HPV 75 | 1 (1.0) | 3 (3.1) | |
HPV 76 | 25 (25.5) | 21 (21.4) | |
HPV 92 | 2 (2.0) | 7 (7.1) | |
HPV 96 | 2 (2.0) | 3 (3.1) |
CI, confidence interval; BCC, basal cell carcinoma; HPV, human papillomavirus; OR, odds ratio; SCC, squamous cell carcinoma.
ORs are adjusted for age, sex, education, smoking, skin sensitivity to sunlight, and lifetime sunburns.